![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics, Safety, and Tolerability of EDP-239,
a novel Hepatitis C NS5A inhibitor, in Healthy Volunteers
|
|
|
Reported by Jules Levin
ICAAC 2015 Sept 17-21 2015 San Diego, CA
Lijuan Jiang1, Xuemin Jiang2, Kiran Dole2, Kimberly Caliri1, Kenneth Tack1, Richard Colvin2, Yat Sun Or1
1 Enanta Pharmaceuticals Inc., Watertown MA; 2 Novartis Institutes for Biomedical Research, Cambridge, MA
![ICAAC1.gif](../images/093015/093015-1/ICAAC1.gif)
![ICAAC2.gif](../images/093015/093015-1/ICAAC2.gif)
![ICAAC3.gif](../images/093015/093015-1/ICAAC3.gif)
![ICAAC4.gif](../images/093015/093015-1/ICAAC4.gif)
![ICAAC5.gif](../images/093015/093015-1/ICAAC5.gif)
![ICAAC6.gif](../images/093015/093015-1/ICAAC6.gif)
![ICAAC7.gif](../images/093015/093015-1/ICAAC7.gif)
![ICAAC8.gif](../images/093015/093015-1/ICAAC8.gif)
![ICAAC9.gif](../images/093015/093015-1/ICAAC9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|